Guardant Health, Inc. (GH)

Guardant Health's stock price has fluctuated over the past six months due to company-specific and market events. In January 2026, the company announced preliminary results for Q4 and full year 2025, with revenue increasing by 39% for Q4 and 33% for the full year. In February 2026, the company reported Q4 CY2025 results, exceeding revenue expectations but missing non-GAAP loss per share estimates. In March 2026, Guardant Health presented at the Barclays 28th Annual Global Healthcare Conference, discussing growth drivers for its products. In early April 2026, analysts offered insights on the company, with Citi adding an upside catalyst watch and Evercore ISI lowering its price target. As of April 10, 2026, the stock price reflected an 11.10% drop since the market opened.

The Healthcare sector generally experiences seasonal strength from April 25 to December 4. Guardant Health Inc. has historically shown positive results from May 9 to September 15 compared to the S&P 500 Total Return Index. However, only 7 years of data are available, which may be insufficient for a reliable seasonal profile.

Guardant Health, Inc. is a precision oncology company focused on improving cancer care through blood and tissue tests, real-world data, and AI analytics. The company operates in the Healthcare sector, specifically in Diagnostics & Research, and develops liquid biopsy tests for cancer diagnosis, treatment, and management. Its major products include Guardant360 for genomic profiling, Guardant Reveal for molecular residual disease testing, and Guardant Shield for colorectal cancer screening. The company also offers research development services.

Guardant Health has a global presence with operations in the United States and Europe. The company is expanding access to its liquid biopsy tests worldwide through partnerships with laboratories and cancer centers. It has offices in Singapore, Japan, China, India, and a presence in Canada.

Guardant Health's brand reputation in the past year appears positive, driven by advancements in liquid biopsy technology and product adoption. The Guardant Shield blood test has demonstrated a high adherence rate, indicating strong patient and physician acceptance. Guardant360 Tissue has shown a high accuracy rate in identifying the origin of unknown primary cancers, and Guardant360 Liquid achieved high actionable finding rates. Guardant Reveal is noted as the fastest-growing oncology product by volume. The company's InfinityAI platform supported Japan's approval of ENHERTU, and it partnered with Verana Health to advance precision medicine. Guardant360 received FDA approval for its CRC indication.

Guardant Health, Inc. has a diverse ownership structure. Institutional investors own approximately 81.06% to 87.23% of the stock. Insiders own about 3.39%, and public companies and individual investors hold around 10.18% to 15.55% of the stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Price T Rowe Associates Inc, Invesco Ltd., Baillie Gifford & Co., Capital International Investors, Franklin Resources Inc., Geode Capital Management, Llc., and State Street Corp.